Literature DB >> 15834600

Trombophilic screening for nonarteritic anterior ischemic optic neuropathy.

Valeria Nagy1, Zita Steiber, Lili Takacs, Gyorgy Vereb, Andras Berta, Zsuzsanna Bereczky, Gyorgy Pfliegler.   

Abstract

BACKGROUND: Nonarteritic anterior ischemic optic neuropathy (NAION) is an ischemic infarction of the optic nerve head, frequently leading to sudden, mostly irreversible loss of vision. In this study blood thrombophilic factors, as well as cardiovascular risk factors were investigated for their relevance to this pathology. Trombophilic risk factors so far not evaluated were included in the study. PATIENTS AND METHODS: 37 NAION patients (4 with sequential second eye involvement) and 81 matched control subjects were examined. From blood, protein C, protein S, antithrombin, von Willebrand antigen levels (vWFAg), and factor V (Leiden) mutation, factor VIIIC level, plasminogen activity, lipoprotein (a) and fibrinogen levels, and presence of anticardiolipin antibodies were investigated. Possibly relevant pathologies [e.g. diabetes mellitus (DM), hypertension, and ischemic heart disease] were also registered.
RESULTS: Elevated Lp(a) and vWFAg levels, DM, F V (Leiden), hypercholesterolemia, and hyperfibinogenemia proved to be significant risk factors associated with NAION. Forward stepwise logistic regression analysis revealed that high Lp(a), DM, and FV (Leiden) were the main predictive components, with odds ratios 16.88 (p=0.012), 5.78 (p=0.022) and 4.44 (p=0.033), respectively.
CONCLUSIONS: Based on our results it appears that thrombophilia is likely to contribute to the development of NAION besides vascular damage due to the presence of cardiovascular risk factors. Further data are needed, however, to justify the suggested use of secondary prophylaxis using anticoagulant/antiplatelet therapy.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15834600     DOI: 10.1007/s00417-005-1154-5

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  33 in total

Review 1.  Central retinal vein occlusion and thrombophilia.

Authors:  C D Fegan
Journal:  Eye (Lond)       Date:  2002-01       Impact factor: 3.775

2.  A single genetic origin for the common prothrombotic G20210A polymorphism in the prothrombin gene.

Authors:  A Zivelin; N Rosenberg; S Faier; N Kornbrot; H Peretz; C Mannhalter; M H Horellou; U Seligsohn
Journal:  Blood       Date:  1998-08-15       Impact factor: 22.113

3.  Standardization of Lp(a) measurements.

Authors:  G M Kostner; A Steinmetz
Journal:  Clin Genet       Date:  1997-11       Impact factor: 4.438

Review 4.  Activated protein C resistance due to a common factor V gene mutation is a major risk factor for venous thrombosis.

Authors:  B Zöller; A Hillarp; E Berntorp; B Dahlbäck
Journal:  Annu Rev Med       Date:  1997       Impact factor: 13.739

5.  Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy.

Authors:  O Salomon; R Huna-Baron; S Kurtz; D M Steinberg; J Moisseiev; N Rosenberg; I Yassur; O Vidne; A Zivelin; S Gitel; J Davidson; B Ravid; U Seligsohn
Journal:  Ophthalmology       Date:  1999-04       Impact factor: 12.079

6.  Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.

Authors:  C Aparicio; B Dahlbäck
Journal:  Biochem J       Date:  1996-01-15       Impact factor: 3.857

7.  Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood.

Authors:  U Nowak-Göttl; R Junker; M Hartmeier; H G Koch; N Münchow; G Assmann; A von Eckardstein
Journal:  Circulation       Date:  1999-08-17       Impact factor: 29.690

Review 8.  Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.

Authors:  B Dahlbäck
Journal:  Semin Thromb Hemost       Date:  1999       Impact factor: 4.180

9.  Plasma lipoprotein(a) levels are high in patients with central retinal artery occlusion.

Authors:  M Murata; T Saito; S Takahashi; A Ichinose
Journal:  Thromb Res       Date:  1998-08-15       Impact factor: 3.944

10.  Nonarteritic anterior ischemic optic neuropathy is associated with a specific platelet polymorphism located on the glycoprotein Ibalpha gene.

Authors:  Ophira Salomon; Nurit Rosenberg; David M Steinberg; Ruth Huna-Baron; Joseph Moisseiev; Rima Dardik; Oren Goldan; Shimon Kurtz; Aviya Ifrah; Uri Seligsohn
Journal:  Ophthalmology       Date:  2004-01       Impact factor: 12.079

View more
  13 in total

1.  Non-arteritic anterior ischemic optic neuropathy and thrombophilia.

Authors:  Sohan Singh Hayreh
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-10-29       Impact factor: 3.117

Review 2.  [Cardiovascular and hemostaseological view of retinal vascular occlusions].

Authors:  H Seidel; E Stegemann; C Heiss
Journal:  Ophthalmologe       Date:  2014-01       Impact factor: 1.059

3.  Thrombophilic risk factors in the pathogenesis of non-arteritic anterior ischemic optic neuropathy patients.

Authors:  Taxiarchis Felekis; Nikolaos I Kolaitis; Georgios Kitsos; Georgios Vartholomatos; Konstantinos L Bourantas; Ioannis Asproudis
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2010-02-17       Impact factor: 3.117

4.  Association Study of MTHFR Polymorphisms with Nonarteritic Anterior Ischemic Optic Neuropathy in a Spanish Population.

Authors:  Beatriz Fernández-Vega; Lydia Álvarez; Montserrat García; Enol Artime; Marta Diñeiro Soto; Javier Nicieza; José A Vega; Héctor González-Iglesias
Journal:  Biomed Hub       Date:  2020-01-21

5.  Increased level of platelet P-selectin in nonarteritic anterior ischemic optic neuropathy.

Authors:  Valeria Nagy; Bence Kolozsvari; Zsuzsa Balogh; Adrienne Csutak; Marta Kasza; Bela Nagy; Laszlo Kardos; Andras Berta; Gyorgy Pfliegler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-11-16       Impact factor: 3.117

6.  Evaluation of traditional and emerging cardiovascular risk factors in patients with non-arteritic anterior ischemic optic neuropathy: a case-control study.

Authors:  Barbara Giambene; Andrea Sodi; Francesco Sofi; Rossella Marcucci; Sandra Fedi; Rosanna Abbate; Domenico Prisco; Ugo Menchini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-12-04       Impact factor: 3.117

Review 7.  Vision disorders and phosphodiesterase type 5 inhibitors: a review of the evidence to date.

Authors:  Alan M Laties
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

Review 8.  Phosphodiesterase type 5 inhibitors, visual changes, and nonarteritic anterior ischemic optic neuropathy: is there a link?

Authors:  Konstantinos Hatzimouratidis
Journal:  Curr Urol Rep       Date:  2007-11       Impact factor: 3.092

9.  Selective thrombophilia screening of patients with nonarteritic anterior ischemic optic neuropathy.

Authors:  Claudia Kuhli-Hattenbach; Inge Scharrer; Marc Lüchtenberg; Lars-Olof Hattenbach
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2008-11-11       Impact factor: 3.117

10.  Protein Z Plasma Levels are Not Elevated in Patients with Non-Arteritic Anterior Ischemic Optic Neuropathy.

Authors:  Ioannis Asproudis; Taxiarchis L Felekis; Spiridon Gorezis; Lefkothea Dova; Eleni Dokou; Georgios Vartholomatos; Miltiadis Aspiotis; Nikolaos I Kolaitis
Journal:  Open Ophthalmol J       Date:  2009-04-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.